Evidence map›Paper›PMID 35538256›Full record

ArticleInternational ophthalmology2022

The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion.

Irini Chatziralli, Dimitrios Kazantzis, Christos Kroupis, Genovefa Machairoudia, Eleni Dimitriou, George Theodossiadis, Panagiotis Theodossiadis, Theodoros N Sergentanis

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Irini Chatziralli2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini street, 12462, Haidari, Athens, Greece. eirchat@yahoo.gr.ORCID http://orcid.org/0000-0001-8523-1024
Dimitrios Kazantzis2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini street, 12462, Haidari, Athens, Greece.
Christos KroupisDepartment of Clinical Biochemistry, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Genovefa Machairoudia2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini street, 12462, Haidari, Athens, Greece.
Eleni Dimitriou2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini street, 12462, Haidari, Athens, Greece.
George Theodossiadis2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini street, 12462, Haidari, Athens, Greece.
Panagiotis Theodossiadis2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Attikon University Hospital, 1, Rimini street, 12462, Haidari, Athens, Greece.
Theodoros N SergentanisDepartment of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate potential laboratory and imaging biomarkers as treatment response predictors to intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in patients with retinal vein occlusion (RVO).

methodsParticipants in this prospective study were 53 patients with treatment naïve macular edema secondary to RVO, treated with intravitreal anti-VEGF agents and followed-up for 12 months. At baseline, all participants underwent best-corrected visual acuity measurement, dilated fundoscopy, optical coherence tomography and fluorescein angiography (FFA), while full blood count and biochemical analysis of various parameters was also performed. At month 12, treatment response was examined and classified as "favorable" or "non-response". Potential associations between laboratory/imaging biomarkers and treatment response were assessed.

resultsUnivariate analysis showed that "favorable" response at month 12 after initiation of anti-VEGF treatment was correlated with baseline central subfield thickness (CST) < 464 μm (p < 0.001), absence of subretinal fluid (p = 0.004), absence of hyperreflective foci (HF) (p = 0.004), intact ellipsoid zone (EZ) and external limiting membrane (ELM) (p < 0.001 and p = 0.001, respectively), absence of epiretinal membrane (ERM) (p = 0.020) and absence of macular ischemia on FFA (p < 0.001), while increased monocytes-to-lymphocytes ratio was also associated with "favorable" treatment response (p = 0.010). All other laboratory parameters did not reach statistical significance. However, at the multivariate analysis, EZ and ELM status, HF, macular ischemia and monocytes-to-lymphocytes ratio were found to be independent predictors of treatment response.

conclusionsIntact EZ and ELM, absence of HF, absence of macular ischemia and increased monocytes-to-lymphocytes ratio at baseline can predict "favorable" treatment response in patients with treatment naïve macular edema secondary to RVO.

Indexed as

Macular EdemaRetinal Vein OcclusionVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabBiomarkersHumansIntravitreal InjectionsIschemiaProspective StudiesRetrospective StudiesTomography, Optical CoherenceVisual AcuityAngiogenesis InhibitorsBevacizumabBiomarkersVascular Endothelial Growth Factor AAnti-VEGFBiomarkersLaboratoryOptical coherence tomographyRetinal vein occlusionTreatment response

Identifiers

PMID35538256
OpenAlexW4280588746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.